Acceptance and adherence with antiretroviral therapy among HIV-infected women in a correctional facility

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 18, Issue 4, 1998, Pages 341-348

  Mostashari, Farzad ^a   Riley, Elise ^a   Selwyn, Peter A ^a   Altice, Frederick L ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adherence; Antiretroviral agents; Drug users; HIV AIDS; Prisons; Women, behavior knowledge attitudes

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ARTICLE; DRUG ABUSE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PRISON;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0032146832     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199808010-00005     Document Type: Article

References (27)

1. Markowitz M, Saag M, Powderly WG, et al. A preliminary study of Ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 1995;333:1534-9.
2. Feinstein AR. "Compliance bias" and the interpretation of therapeutic trials. In Haynes RB, Taylor DW, and Sackett DL, eds. Compliance in health care. Baltimore: Johns Hopkins University Press. 1979:309-22.
3. Update: mortality attributable to HIV infection among persons aged 25-44 years - United States, 1994. MMWR Morb Mortal Wkly Rep 1996;45:121-5.
4. Moore RD, Hidalgo J, Sugland BW, Chaisson RE. Zidovudine and the natural history of the acquired immunodeficiency syndrome. N Engl J Med 1991;324:1412-6.
5. Melnick SL, Sherer R, Louis TA, et al. Survival and disease progression according to gender of patients with HIV infection. The Terry Beirn Community Programs for clinical research on AIDS. JAMA 1994;272:1915-24.
6. Mor V, Fleishman JA, Dresser M, Piette J. Variation in health service use among HIV-infected patients. Med Care 1992;30:17-29.
7. Moore RD, Hidalgo J, Bareta JC, Chaisson RE. Zidovudine therapy and health resource utilization in AIDS. J Acquir Immune Defic Syndr 1994;7:349-54.
8. Easterbrook PJ, Chmiel JS, Hoover DR, et al. Racial and ethnic differences in human immunodeficiency virus type 1 (HIV-1) seroprevalence among homosexual and bisexual men. The Multicenter AIDS Cohort Study. Am J Epidemiol 1993;138:415-29.
9. El-Sadr W, Capps L. The challenge of minority recruitment in clinical trials for AIDS. JAMA 1992;267:954-7.
10. Centers for Disease Control and Prevention. HIV/AIDS surveillance report. Atlanta: Division of HIV/AIDS Prevention, 1995.
11. Chaisson RE. Race, sex, drug use, and progression of human immunodeficiency virus disease. N Engl J Med 1995;333:751-6.
12. Bureau of Justice Statistics. Sourcebook of criminal justice statistics - 1993. Washington, DC: U.S. Department of Justice, 1994.
13. Tanguay SM, Altice FL, Hunt DH. Demographic, risk behavior, and gender difference of HIV+ inmates in Connecticut [abstract PO-C21-3103], Presented at the IX International Conference on AIDS, Berlin, Germany, 1993.
14. Hammer, SM. Advances in antiretroviral therapy and viral load monitoring [review]. AIDS 1996;10(Suppl 3):S1-11.
15. Gazzard, B. What we know so far [review]. AIDS 1996; 10(Suppl 1):S3-7.
16. Moore RD, Hidalgo J, Bareta JC, Chaisson RE. Zidovudine therapy and health resource utilization in AIDS. J Acquir Immune Defic Syndr 1994;7:349-54.
17. Jones JH. Bad blood: the Tuskeegee syphilis experiment. New York: Free Press, 1993.
18. Samet JH, Libman H, Steger KA, et al. Compliance with zidovudine therapy in patients infected with human immunodeficiency virus, type 1: a cross-sectional study in a municipal hospital clinic. Am J Med 1992; 92:495-501.
19. Muma RD, Ross MW, Parcel GS, Pollard RB. Zidovudine adherence among individuals with HIV infection. AIDS Care 1995;7: 439-47.
20. Selwyn PA, Budner NS, Wasserman WC, Arno PS. Utilization of on-site primary care services by HIV-seropositive and seronegative drug users in a methadone maintenance program. Public Health Rep 1993;108:492-500.
21. O'Connor PG, Molde S, Henry S, Shockcor WT, Schottenfeld RS. Human immunodeficiency virus infection in injection drug users: a model for primary care. Am J Med 1992;93:382-6.
22. Solomon L, Vlahov D, Astemborski J, Galai N, Graham NMH, Nelson KE. Factors associated with initiation of zidovudine in a cohort of injection drug users. J Drug Issues 1995;25:225-33.
23. Flanigan TP, Kim JY, Zierler S, et al. A prison release program for HIV positive women: linking them to health services and community follow-up [letter]. Am J Pub Health 1996;86:886-7.
24. Health Resources and Service Administration, Bureau of Health Resources Department, Office of Science and Epidemiology. Progress and challenges in linking incarcerated individuals with HIV/AIDS to community services. Washington, DC: U.S. Government Printing Office, 1995.
25. Altice FL, Khoshnood K, Appicelli, M. Transitional case management for HIV+ prisoners in Connecticut. Presented at the National Conference on Women and HIV, Pasadena, CA, May 4-7, 1997.
26. Cochran SD, Mays VM. Applying social psychological models to predicting HIV-related sexual risk behaviors among African-Americans. J Black Psychol 1993;19:142-54.
27. Meyers K, Metzger DA, McLellan TA, Navaline H, Sheon AR, Woody GE. Will preventive vaccine efficacy trials be possible with female injection drug users? J Acquir Immune Defic Syndr Hum Retrovirol 1995;10:577-85.